CMV-specific CD8+ T-cell function is not impaired in chronic lymphocytic leukemia

Blood

Volumn 123, Issue 5, 2014, Pages 717-724

  Te Raa, G Doreen ^a,b   Pascutti, Maria Fernanda ^a,b   García Vallejo, Juan J ^c   Reinen, Emilie ^a   Remmerswaal, Ester B M ^b   Ten Berge, Ineke J M ^b   Van Lier, René A W ^d   Eldering, Eric ^b,e   Van Oers, Marinus H J ^a,e   Tonino, Sanne H ^a,e   Kater, Arnon P ^a,e  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d CENTRAL LABORATORY   (Netherlands)

^e Lymphoma and Myeloma Center Amsterdam (LYMMCARE)   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD160 ANTIGEN; CD244 ANTIGEN; IONOMYCIN; PHORBOL 13 ACETATE 12 MYRISTATE; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG; CYTOKINE;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOLOGICAL SYNAPSE; LYMPHOCYTE FUNCTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; CYTOMEGALOVIRUS; IMMUNOLOGY; VIROLOGY;

CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; CYTOMEGALOVIRUS; HUMANS; IMMUNOLOGICAL SYNAPSES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;

EID: 84894031954     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-08-518183     Document Type: Article

References (49)

1. Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol. 1999;17(1):399-408. (Pubitemid 29022419)
2. Hamblin AD, Hamblin TJ. The immunodeficiency of chronic lymphocytic leukaemia. Br Med Bull. 2008;87:49-62.
3. Christopoulos P, Pfeifer D, Bartholomé K, et al. Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. Blood. 2011;117(14):3836-3846.
4. Görgün G, Holderried TA, Zahrieh D, Neuberg D, Gribben JG. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest. 2005;115(7):1797-1805. (Pubitemid 40979718)
5. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118(7):2427-2437. (Pubitemid 351949771)
6. Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood. 2012;120(7):1412-1421.
7. Riches JC, Davies JK, McClanahan F, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013;121(9):1612-1621.
8. Krackhardt AM, Harig S, Witzens M, Broderick R, Barrett P, Gribben JG. T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy. Blood. 2002;100(1):167-173. (Pubitemid 35177443)
9. Goolsby CL, Kuchnio M, Finn WG, Peterson L. Expansions of clonal and oligoclonal T cells in B-cell chronic lymphocytic leukemia are primarily restricted to the CD3(+)CD8(+) T-cell population. Cytometry. 2000;42(3):188-195. (Pubitemid 30451719)
10. Serrano D, Monteiro J, Allen SL, et al. Clonal expansion within the CD4+CD57+ and CD8+ CD57+ T cell subsets in chronic lymphocytic leukemia. J Immunol. 1997;158(3):1482-1489. (Pubitemid 127469977)
11. Mackus WJ, Frakking FN, Grummels A, et al. Expansion of CMV-specific CD8+CD45RA+ CD27- T cells in B-cell chronic lymphocytic leukemia. Blood. 2003;102(3):1057-1063. (Pubitemid 36917804)
12. Kuijpers TW, Vossen MT, Gent MR, et al. Frequencies of circulating cytolytic, CD45RA+ CD27-, CD8+ T lymphocytes depend on infection with CMV. J Immunol. 2003;170(8):4342-4348. (Pubitemid 36428204)
13. Pourgheysari B, Bruton R, Parry H, et al. The number of cytomegalovirus-specific CD4+ T cells is markedly expanded in patients with B-cell chronic lymphocytic leukemia and determines the total CD4+ T-cell repertoire. Blood. 2010;116(16):2968-2974.
14. Tonino SH, van de Berg PJ, Yong SL, et al. Expansion of effector T cells associated with decreased PD-1 expression in patients with indolent B cell lymphomas and chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53(9):1785-1794.
15. van Leeuwen EM, Remmerswaal EB, Heemskerk MH, ten Berge IJ, van Lier RA. Strong selection of virus-specific cytotoxic CD4+ T-cell clones during primary human cytomegalovirus infection. Blood. 2006;108(9):3121-3127.
16. van Aalderen MC, Remmerswaal EB, Heutinck KM, et al. Phenotypic and functional characterization of circulating polyomavirus BK VP1-specific CD8+ T cells in healthy adults. J Virol. 2013;87(18):10263-10272.
17. Kater AP, Remmerswaal EB, Nolte MA, Eldering E, van Oers MH, van Lier RA. Autologous cytomegalovirus-specific T cells as effector cells in immunotherapy of B cell chronic lymphocytic leukaemia. Br J Haematol. 2004;126(4):512-516. (Pubitemid 39093093)
18. Lamoreaux L, Roederer M, Koup R. Intracellular cytokine optimization and standard operating procedure. Nat Protoc. 2006;1(3):1507-1516.
19. Remmerswaal EB, Havenith SH, Idu MM, et al. Human virus-specific effector-type T cells accumulate in blood but not in lymph nodes. Blood. 2012;119(7):1702-1712.
20. van Leeuwen EM, Gamadia LE, Baars PA, Remmerswaal EB, ten Berge IJ, van Lier RA. Proliferation requirements of cytomegalovirusspecific, effector-type human CD8+ T cells. J Immunol. 2002;169(10):5838-5843. (Pubitemid 35291687)
21. Serriari NE, Gondois-Rey F, Guillaume Y, et al. B and T lymphocyte attenuator is highly expressed on CMV-specific T cells during infection and regulates their function. J Immunol. 2010;185(6):3140-3148.
22. Flanagan WM, Corthésy B, Bram RJ, Crabtree GR. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature. 1991;352(6338):803-807. (Pubitemid 21912434)
23. Converse PJ, Hess AD, Tutschka PJ, Santos GW. Effect of cyclosporine on the response of normal human lymphocytes to cytomegalovirus in vitro. Infect Immun. 1983;41(3):1226-1233. (Pubitemid 13048601)
24. Hess AD, Tutschka PJ. Effect of cyclosporin A on human lymphocyte responses in vitro. I. CsA allows for the expression of alloantigen-activated suppressor cells while preferentially inhibiting the induction of cytolytic effector lymphocytes in MLR. J Immunol. 1980;124(6):2601-2608. (Pubitemid 10116027)
25. Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492-499.
26. Morrison VA. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol. 2010;23(1):145-153.
27. Moreira J, Rabe KG, Cerhan JR, et al. Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls. Leukemia. 2013;27(1):136-141.
28. te Raa GD, Tonino SH, Remmerswaal EB, et al. Chronic lymphocytic leukemia specific T-cell subset alterations are clone-size dependent and not present in monoclonal B lymphocytosis. Leuk Lymphoma. 2012;53(11):2321-2325.
29. van Leeuwen EM, de Bree GJ, ten Berge IJ, van Lier RA. Human virus-specific CD8+ T cells: diversity specialists. Immunol Rev. 2006;211:225-235.
30. van Lier RA, ten Berge IJ, Gamadia LE. Human CD8(+) T-cell differentiation in response to viruses. Nat Rev Immunol. 2003;3(12):931-939.
31. Appay V, van Lier RA, Sallusto F, Roederer M. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A. 2008;73(11):975-983.
32. Hamann D, Kostense S, Wolthers KC, et al. Evidence that human CD8+CD45RA+CD27-cells are induced by antigen and evolve through extensive rounds of division. Int Immunol. 1999;11(7):1027-1033. (Pubitemid 29338743)
33. Appay V, Dunbar PR, Callan M, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002;8(4):379-385. (Pubitemid 34407033)
34. Hamann D, Baars PA, Rep MH, et al. Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med. 1997;186(9):1407-1418. (Pubitemid 27479800)
35. Kater AP, van Oers MH, Kipps TJ. Cellular immune therapy for chronic lymphocytic leukemia. Blood. 2007;110(8):2811-2818. (Pubitemid 350006933)
36. Bratke K, Kuepper M, Bade B, Virchow JC Jr, Luttmann W. Differential expression of human granzymes A, B, and K in natural killer cells and during CD8+ T cell differentiation in peripheral blood. Eur J Immunol. 2005;35(9):2608-2616. (Pubitemid 41404044)
37. van Leeuwen EM, de Bree GJ, Remmerswaal EB, et al. IL-7 receptor alpha chain expression distinguishes functional subsets of virus-specific human CD8+ T cells. Blood. 2005;106(6):2091-2098. (Pubitemid 41291724)
38. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341-1349. (Pubitemid 350060129)
39. Brusa D, Serra S, Coscia M, et al. The PD-1/PDL1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica. 2013;98(6):953-963.
40. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439(7077):682-687. (Pubitemid 43237609)
41. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465.
42. John LB, Devaud C, Duong CP, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by genemodified T cells. Clin Cancer Res. 2013;19(20):5636-5646.
43. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443- 2454.
44. Wei F, Zhong S, Ma Z, et al. Strength of PD-1 signaling differentially affects T-cell effector functions. Proc Natl Acad Sci USA. 2013;110(27):E2480- E2489.
45. Karrer U, Sierro S, Wagner M, et al. Memory inflation: continuous accumulation of antiviral CD8+ T cells over time. J Immunol. 2003;170(4):2022-2029. (Pubitemid 36197423)
46. Snyder CM. Buffered memory: a hypothesis for the maintenance of functional, virus-specific CD8(+) T cells during cytomegalovirus infection. Immunol Res. 2011;51(2-3):195-204.
47. Gamadia LE, Rentenaar RJ, Baars PA, et al. Differentiation of cytomegalovirus-specific CD8(+) T cells in healthy and immunosuppressed virus carriers. Blood. 2001;98(3):754-761.
48. Foa R, Lauria F, Lusso P, et al. Discrepancy between phenotypic and functional features of natural killer T-lymphocytes in B-cell chronic lymphocytic leukaemia. Br J Haematol. 1984;58(3):509-516. (Pubitemid 14017200)
49. Katrinakis G, Kyriakou D, Papadaki H, Kalokyri I, Markidou F, Eliopoulos GD. Defective natural killer cell activity in B-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor-alpha. Acta Haematol. 1996;96(1):16-23. (Pubitemid 26187968)